Itoco (Dorzolamide)

Dorzolamide blocks carbonic anhydrase enzymes in the ciliary body of the eye. This inhibition reduces the production of aqueous humor, the fluid that maintains eye pressure, thereby lowering intra‑ocular pressure and mitigating the risk of glaucoma progression.

The specific dosing regimen for Itoco is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) two to three times daily, but the exact frequency and duration are individualized based on the patient’s condition and response.

Safety data for dorzolamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Itoco, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itoco (dorzolamide) belongs to the carbonic anhydrase inhibitor class, whereas many alternatives such as timolol are beta‑blockers. Dorzolamide reduces aqueous humor production, while beta‑blockers decrease its secretion. Choice of therapy depends on patient tolerance, comorbidities, and desired IOP‑lowering profile.

Itoco should be stored at room temperature, ideally below 25 °C, in its original container. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the solution.

Itoco is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac. Avoid touching the dropper tip to the eye or any surface to maintain sterility.

The most serious adverse reactions include severe allergic responses such as angioedema or anaphylaxis, and rare skin conditions like Stevens‑Johnson syndrome. If any signs of a severe reaction appear—such as swelling, rash, or sudden vision loss—seek immediate medical attention.

Itoco should be avoided in individuals with a known hypersensitivity to dorzolamide, other sulfonamides, or any component of the formulation. Patients with severe renal impairment should use it only under close medical supervision, and those on conflicting ocular medications should be evaluated by a clinician.